• EMBRAVE (vaginal cancer):

A prospective multi-center clinical registration study on chemoradiotherapy and IGABT in vaginal cancer (EMBRAVE). Following the GEC-ESTRO/ABS/CBG target concept publications, this study aims to validate the target concept and provide benchmark results and derive evidence based recommendations for dose planning aims and constraints for vaginal cancer.

Principal Investigator: Remi Nout, Henrike Westerveld
For further details: NCT06514235/MEC-2021-0820

 

• EMBRACE III triplet studies (cervical cancer):

REWIND: This is retrospective datacollection of MRI based brachytherapy in EMBRACE II centres
Principal Investigator: Primoz Petric.

PROMISE: This is a prospective data collection of patients treated for locally advanced cervical cancer with MRI based brachytherapy.
Principal Investigator: Maximilian Schmid.

IMPACT (CT guided brachytherapy) – The study is Multicentric international study for implementation of IBS-GECESTRO-ABS recommendations for CT based brachytherapy.
Principal Investigator: Umesh Mahantshetty
For further details: NCT07249021.

 

• Phase II single arm study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: EMBRACE High risk study initiative

This study will open in international sites in 2026 and will test addition of Pembrolizumab and Lenvatinib chemoradiation and image guided brachytherapy.  The study will begin recruitment end 2026-early 2027.

Principle Investigator: Remi Nout, Supriya Chopra, Ingrid Boere
For further details: NCT07368985/ 2023-506982-73-00 (EU Trial (CTIS) Number

 

• RAPID study: Response Adapted Precise and Individualised Radiotherapy Dose Prescription in favorable risk locally advanced Cervix Cancer

A phase II single-arm study on Response Adapted Precise and Individualized radiotherapy dose Prescription in favorable risk locally advanced Cervical Cancer. The study will initiate recruitment in 2027.

Principal Investigator: Remi Nout, Kari Tanderup.